HOME >> BIOLOGY >> NEWS
Cytokinetics presents data on CK-1827452

South San Francisco, CA, September 19, 2005 Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the company presented a scientific poster on CK-1827452, a novel small molecule activator of cardiac myosin, today at the 2005 Annual Heart Failure Society of America Meeting in Boca Raton, Florida. The moderated oral poster presentation highlighted data relating to the mechanism of action of CK-1827452 as well as its characterization in a heart failure model in animals. CK-1827452 is the first clinical drug candidate to arise from the company's cardiac myosin activator program, research that leverages Cytokinetics' expertise in cytoskeletal pharmacology and muscle contractility. CK-1827452 is currently the subject of a first-time-in-human Phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of this novel drug candidate.

The poster titled, "Direct Activation of Cardiac Myosin by CK-1827452 Improves Cardiac Function in a Dog Heart Failure Model." [Poster Presentation #017] has been displayed today and will be presented at 5:45 pm ET by Fady Malik, M.D., Ph.D., F.A.C.C., Director, Cardiovascular Programs, Cytokinetics. The presentation details research directed to the discovery and optimization of small molecules that improve cardiac function in a manner consistent with the therapeutic hypothesis, specifically that improving cardiac contractility by directly activating cardiac myosin can potentially address the liabilities of current inotropic drugs. The data demonstrate that CK-1827452 selectively activates cardiac myosin. In cardiac myocytes, CK-1827452 increases contractility without changes in the cellular calcium transient, a finding consistent with its mechanism of action. In addition, CK-1827452 demonstrates an improvement in cardiac function and output, hemodynamics and efficiency in a dog model of heart failure in a manner that supports the therapeutic hypothesis.

The presen
'"/>

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006
Burns McClellan
19-Sep-2005


Page: 1 2 3 4

Related biology news :

1. Progenika Biopharma presents a biochip that guarantees safety in blood transfusions
2. SNM presents awards on Capitol Hill
3. ESA presents the sharpest ever satellite map of Earth
4. New book presents neurobiology from an evolutionary perspective
5. Lighting up life: Cold Spring Harbor Protocols presents tips for creating glowing plants
6. Childrens Hospital and Research Center-Oakland presents a new maternal diet study
7. USGS presents a world of science at GSA in Philadelphia
8. Childrens Hospital Boston presents at the 2006 American Academy of Pediatrics National Conference
9. DFG presents the 2006 MAK and BAT value list
10. Childrens Hospital Boston presents at the 2006 Pediatric Academic Societies annual meeting
11. Kereos presents at AAAS, discusses nanotech-based disease diagnosis and treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... June 25, 2020 , ... In an upcoming episode ... in accelerated Point of Care Testing solutions (POCT). Check local listings for more info. ... at medical offices and are shipped to labs throughout the country. Results are then ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... and Renovagen Ltd, a UK supplier and manufacturer of innovative portable renewable energy ... operations in the fight against the COVID-19 pandemic in Zambia. , One of ...
(Date:6/23/2020)... ... June 23, 2020 , ... In its June 22 online post, ... Dr. James L. Sherley, M.D., Ph.D., founder and director of stem cell biotechnology company ... on June 16 that starting July 5 it would begin offering free ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... July 17, 2020 , ... ... for the life sciences and food industries, is pleased to announce that Charles ... Research – Business Development. , Charles is an accomplished and results-driven sales executive ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... announced today that Massachusetts Institute of Technology (MIT) has expanded the company’s ... allows PathSensors to move into the point-of-care diagnostic market, focusing initially on ...
(Date:7/10/2020)... (PRWEB) , ... July 09, 2020 , ... ... to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., ... and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson ...
(Date:7/7/2020)... ... July 06, 2020 , ... Bio-IT World has ... Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, Mission: Cure, and ... elite awards program, highlighting outstanding examples of how technology innovations and strategic initiatives ...
Breaking Biology Technology:
Cached News: